Revolution Medicines reported $198 million in third-quarter 2026 sales for Rasonque in its first five weeks following FDA approval on August 26, 2026. The pancreatic cancer drug treated over 5,000 U.S. patients across 2,700 prescribers. While analysts raised revenue projections based on strong reimbursement and survival clinical data, executives noted sales reflected an initial early-access patient influx.
Initial commercial adoption and reach
- ▪Approximately 2,700 prescribers wrote prescriptions for Rasonque through September 30, 2026, with 40% located in academic settings and the remainder in community practices
- ▪Health plans covering more than 90% of patients were reimbursing claims for Rasonque as of November 2026
- ▪More than 5,000 patients in the United States received treatment with Rasonque in the five weeks through September 30, 2026
Drug mechanism and clinical trial efficacy
- ▪Clinical trial research demonstrated Rasonque almost doubled survival times for patients diagnosed with metastatic pancreatic ductal adenocarcinoma
- ▪Rasonque is a pan-RAS inhibitor targeting genetic mutations associated with multiple tumor types
Q3 2026 financial performance and factors
- ▪Revolution Medicines set a list price of $39,800 for a 30-day supply of Rasonque
- ▪Rasonque third-quarter 2026 revenue included a one-time sales boost from transitioning patients enrolled in an early access program
- ▪Revolution Medicines reported $198 million in third-quarter 2026 revenue for Rasonque over five weeks following FDA approval, exceeding financial analyst forecasts of $50 million to $100 million
Analyst reactions and sales forecasts
- ▪Stifel analyst Laura Prendergast stated Rasonque is disrupting standard treatment for pancreatic adenocarcinoma
- ▪RBC Capital Markets analyst Leonid Timashev projected Rasonque fourth-quarter 2026 sales of $426 million and estimated annual sales could exceed $3 billion in 2027
Management commentary on launch trajectory
- ▪Revolution Medicines executives cautioned investors that five weeks of commercial activity is insufficient to establish Rasonque's long-term sales trajectory
- ▪Revolution Medicines Chief Commercial Officer Anthony Mancini stated on an earnings call that the United States launch of Rasonque was off to a strong start
Story comments
Loading comments…